展商风采丨南通伊仕生物技术股份有限公司邀您参加2022北京国际生命健康产业跨境博
南通伊仕生物技术股份有限公司
Nantong Egens Biotechnology Co.,Ltd
邀您参加2022北京国际生命健康产业跨境博览会
展位号：3035、3036
参展产品
COVID-19 Antigen Rapid Test Kit (Oral Saliva)
新型冠状病毒抗原唾液检测试剂盒（胶体金法）
COVID-19 Antigen Rapid Test Kit
新型冠状病毒抗原检测试剂盒（胶体金法）
COVID-19 Neutralization Antibody Rapid Test Kit
新型冠状病毒中和抗体检测试剂盒（荧光免疫层析法）
COVID-19 Neutralization Antibody ELISA Test
新型冠状病毒中和抗体检测试剂盒（酶联免疫法）
产品介绍
2020年，新冠病毒肺炎（COVID-19）肆虐，伊仕生物迅速组织力量，联合医疗科研机构的专家成功研发系列新型冠状病毒 （2019-nCoV ）快速检测试剂盒，快速检测试剂突破了核酸检测方法对人员及场所的限制；不需要借助专用仪器设备，肉眼就可以判断结果；检测用时短，方便快捷；可以检测多种样本。有利于病毒感染诊断和排除可疑病例，对控制病毒传播有重大意义。
In 2020,COVID-19 has raged,Nantong Egens Biotechnology Co., Ltd quickly organized forces,A series of Novel Coronavirus (2019-NCOV) rapid test kits have been successfully developed by experts from the joint medical research institutions,Rapid test reagent breaks through the restriction of nucleic acid testing method on personnel and site;No need to use special instruments and equipment, the naked eye can judge the results;Detection time is short, convenient and quick;It can test a variety of samples.It is beneficial to the diagnosis of virus infection and the elimination of suspicious cases, which is of great significance to the control of virus transmission.
新型冠状病毒中和抗体检测试剂盒（胶体金法）
为满足及时排查新冠疑似患者及无症状感染者的检测需求，我公司利用基因工程技术、单克隆抗体制备技术及免疫层析技术研制出新型冠状病毒抗原快速检测试剂。有利于早期诊断和排除新冠可疑病例。
本试剂盒用于体外定性检测鼻咽拭子中的新型冠状病毒抗原，用于新型冠状病毒感染的临床辅助诊断。
新型冠状病毒中和抗体检测试剂盒（胶体金法）
新型冠状病毒中和抗体检测试剂盒（胶体金法)用于在接种新冠疫苗后，对人体血清、血浆和全血中中和抗体进行体外定性检测。
随着疫苗的研制成功并广泛应用，可作为疫苗效果的评价指标。中和抗体的检测可决定是否能够更安全地重返工作岗位或参加更多的社交活动，评估人群有无再度感染的风险。
新冠病毒中和抗体检测试剂盒(酶联免疫法)
检测样本：血清、血浆 规格：96T/盒
展会地址
中国国际展览中心（老馆）：北京朝阳区北三环东路6号
展会日期
2022年3月19日 09：00-17：00
2022年3月20日 09：00-17：00
2022年3月21日 09：00-14：00
公司介绍
南通伊仕生物技术股份有限公司（以下简称“公司”或“伊仕生物”）成立于1999年，是集生物原料开发、诊断试剂制造、国内外贸易于一体的综合性生物技术公司，为江苏省高新技术企业。
伊仕生物迄今已通过IS 09001,IS 014001,IS 045001,TüV、SüD的ISO 13485、MDSAP体系认证。2013年4月成立伊仕生物研究院，设江苏省纳米抗体工程技术研究中心，博士后科研工作站，涉及诊断和抗体药物开发等领域。在北京科卫临床诊断试剂有限公司设立了研究分部。
截止2021年11月11日，公司及其子公司拥有发明专利27项，实用新型专利52项，在审国家专利18项。
北京科卫临床诊断试剂有限公司是伊仕生物的全资子公司，位于北京怀柔区雁西湖畔国家纳米产业园,由解放军302医院试剂厂2004年改制成立，是集研发生产销售一体的IVD试剂供应商；亚特斯（中国）有限公司（Adaltis China Limited）是伊仕生物的控股子公司，于2013年伊仕生物与意大利亚特斯共同发起成立；上海伊仕泽源生物医学技术有限公司成立于2017年6月，伊仕生物占股 80%，主要为临床及早诊断急性肾损伤提供先进的诊断工具，开发临床检验和床旁即时诊断用急性肾损伤系列诊断试剂盒；2016年12月，伊仕生物参股两家境外公司，意大利亚特斯有限公司与意大利ISE有限公司；2020年7月，注册成立麦迪生医疗科技（南通）有限公司；2021年9月，设立美赞医学检验所（南通）有限公司；2021年10月，控股无锡市欧普兰科技有限公司；2021年11月，控股北京纳捷诊断试剂有限公司。
伊仕生物努力在未来成为家庭生殖健康检测领域的领导者，中国禁毒事业的主要参与者，在临床的快速免疫检测、分子诊断等方面具有重要影响力的综合服务商。我们的愿景是造就一个国际化的、先进的、快速诊断 IVD 研发、制造、服务平台。
上下拉动查看英文公司介绍
Nantong Egens Biotechnology Co., Ltd
Nantong Egens Biotechnology Co., Ltd was founded in 1999.It is a comprehensive biotechnology company integrating biological raw material development, diagnostic reagent manufacturing, and domestic and foreign trade .It is a high-tech enterprise in Jiangsu Province.
Nantong Egens Biotechnology Co., Ltd has passed ISO13485, MDSAP system certification of IS09001, IS014001, IS045001, TüV, SüD.In April 2013,We have established Egens Biotechnology Research Institute,set up Jiangsu Nano Antibody Engineering technology Research Center and postdoctoral research station,covering fields such as diagnosis and antibody drug development.A research branch was set up in Beijing Kewei Clinical Diagnostic Reagent Inc.
As of November 11, 2021,the company and its subsidiaries have 27 invention patents, 52 utility model patents, and 18 national patents under review .
Beijing Kewei Clinical Diagnostic Reagent Inc is a wholly-owned subsidiary of Nantong Egens Biotechnology Co., Ltd. It is located in Yanxi Lake National Nano Industrial Park, Huairou District, Beijing, it was restructured and established in 2004 by 302 Hospital reagent Factory of PLA,It is an IVD reagent that integrates R&D, production and sales supplier; Adaltis China Limited is a holding subsidiary of Nantong Egens Biotechnology Co., Ltd. It was established in 2013 by Nantong Egens Biotechnology Co., Ltd and Italy Ates. Shanghai Yishizeyuan Biomedical Technology Co., Ltd. was established in June 2017,Nantong Egens Biotechnology Co., Ltd owns 80% of the shares,It mainly provides advanced diagnostic tools for early clinical diagnosis of acute kidney injury, and develops clinical tests and bedside instant diagnosis of acute kidney injury.In December 2016,Nantong Egens Biotechnology Co., Ltd shares in two overseas companies,Italy Artes Co., Ltd and Italy ISE Co., Ltd;In July 2020,registered MEDsan Medical Technology (Nantong) Co., Ltd;In September 2021,registered Mezan Medical Laboratory (Nantong) Co., Ltd;In October 2021,holding Wuxi Opland Technology Co., Ltd;In November 2021,holding Beijing Najie Diagnostic Reagent Co., Ltd.
Nantong Egens Biotechnology Co., Ltd strives to become a leader in the field of family reproductive health testing in the future, a major participant in China's anti-drug cause, and a comprehensive service provider with important influence in clinical rapid immunoassay and molecular diagnosis.Our vision is to create an international, advanced, rapid diagnostic IVD research and development, manufacturing, service platform.
Company development history(condensed version)
In December 1999,Nantong Egens Biotechnology Co., Ltd was established;
In 2007, Nantong Egens Biotechnology Co., Ltd started to develop the international market, successfully applied for the right to import and export,and and passed the European Union (CE) certification, ISO14001, ISO9001, 13485 and other system certifications;
In 2013, the Dongda-Egens Nano antibody Joint Research and Development Center cooperation between Egens and Southeast University was awarded as Jiangsu NanoAntibody Application Engineering Technology Research Center, and was approved as a national postdoctoral research workstation branch in the same year;
In December 2013, the wholly-owned acquisition of Beijing Kewei Clinical Diagnostic Reagent Inc.
In December 2013, Nantong Egens Biotechnology Co., Ltd and Italian Artes Co., Ltd jointly set up Artes (China) Co., Ltd in Hong Kong;
In April 2014, Nantong Egens Testing Equipment Co., Ltd was established；
In April 2015, Nantong Egens Trading Co., Ltd was established, and the name was changed to Nantong Egens Electronic Commerce Co., Ltd. in August 2019;
In September 2015, the company's shareholding restructuringthe ,the overall change and the establishment of Nantong Egens Biotechnology Co., Ltd;
In December 2016, we took a stake in Italy ISE Co., Ltd and Italian Artes Co., Ltd;
In June 2017, Shanghai Yishizeyuan Biomedical Technology Co., Ltd was established;
In July 2020, MEDsan Medical Technology (Nantong) Co., Ltd was established;
In July 2020, Egens(Hong Kong) Holdings Co., Ltd was established;
In September 2021, Mezan Medical Laboratory (Nantong) Co., Ltd was established;
In October 2021,the holding of Wuxi Opland Technology Co., Ltd.
In November 2021,the holding of Beijing Najie Diagnostic Reagent Co., Ltd.
加入CLHE
国家商务部、卫健委、中医局进一步部署及外国政府、部分驻华使馆、重要医疗产业机构的合作对接需求，为推动中国跨境医疗合作步伐及医疗产业的融合发展，中国国际商会、商务部外贸发展事务局、世界中医药学会联合会、中国研究型医院学会等重要机构将于2022年3月19日-21日在中国国际展览中心举办2022北京国际生命健康产业跨境博览会，省市商务厅局积极组织企业参加。
博览会共划分八大展区：医疗器械展区、生物医药科技展区、劳保用品及卫生防疫展区、中医药健康产业展区、医疗美容展区、营养保健展区、制药原料及设备展区和数字健康展区。